Active site profiling reveals coupling between domains in SRC-family kinases

Nature Chemical Biology

Volumn 9, Issue 1, 2013, Pages 43-50

  Krishnamurty, Ratika ^a   Brigham, Jennifer L ^a   Leonard, Stephen E ^a   Ranjitkar, Pratistha ^a   Larson, Eric T ^a   Dale, Edward J ^a   Merritt, Ethan A ^b   Maly, Dustin J ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATE; ATP COMPETITIVE INHIBITOR; ENZYME INHIBITOR; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CELL LYSATE; CONTROLLED STUDY; CROSS LINKING; ENZYME ACTIVATION; ENZYME ACTIVE SITE; ENZYME CONFORMATION; ENZYME INHIBITION; NONHUMAN; PHOTOAFFINITY LABELING; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; QUANTITATIVE ANALYSIS;

ADENOSINE TRIPHOSPHATE; BINDING SITES; CATALYTIC DOMAIN; MODELS, MOLECULAR; PHOTOAFFINITY LABELS; PROTEIN CONFORMATION; SRC-FAMILY KINASES;

EID: 84871335698     PISSN: 15524450     EISSN: 15524469     Source Type: Journal    
DOI: 10.1038/nchembio.1118     Document Type: Article

References (50)

1. Manning, G., Whyte, D.B., Martinez, R., Hunter, T. & Sudarsanam, S. The protein kinase complement of the human genome. Science 298, 1912-1934 (2002).
2. Cohen, P. Protein kinases - the major drug targets of the twenty-first century? Nat. Rev. Drug Discov. 1, 309-315 (2002).
3. Zhang, J., Yang, P.L. & Gray, N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer 9, 28-39 (2009).
4. Cravatt, B.F., Wright, A.T. & Kozarich, J.W. Activity-based protein profiling: from enzyme chemistry to proteomic chemistry. Annu. Rev. Biochem. 77, 383-414 (2008).
5. Barglow, K.T. & Cravatt, B.F. Activity-based protein profiling for the functional annotation of enzymes. Nat. Methods 4, 822-827 (2007).
6. Simon, G.M. & Cravatt, B.F. Activity-based proteomics of enzyme superfamilies: serine hydrolases as a case study. J. Biol. Chem. 285, 11051-11055 (2010).
7. Bantscheff, M. et al. Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors. Nat. Biotechnol. 25, 1035-1044 (2007).
8. Patricelli, M.P. et al. In situ kinase profiling reveals functionally relevant properties of native kinases. Chem. Biol. 18, 699-710 (2011).
9. Sharma, K. et al. Proteomics strategy for quantitative protein interaction profiling in cell extracts. Nat. Methods 6, 741-744 (2009).
10. Cheng, H.C. et al. Allosteric networks governing regulation and catalysis of Src-family protein tyrosine kinases: implications for disease-associated kinases. Clin. Exp. Pharmacol. Physiol. 37, 93-101 (2010).
11. Kim, L.C., Song, L. & Haura, E.B. Src kinases as therapeutic targets for cancer. Nat. Rev. Clin. Oncol. 6, 587-595 (2009).
12. Huse, M. & Kuriyan, J. The conformational plasticity of protein kinases. Cell 109, 275-282 (2002).
13. Boggon, T.J. & Eck, M.J. Structure and regulation of Src family kinases. Oncogene 23, 7918-7927 (2004).
14. Karaman, M.W. et al. A quantitative analysis of kinase inhibitor selectivity. Nat. Biotechnol. 26, 127-132 (2008).
15. Hantschel, O., Rix, U. & Superti-Furga, G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk. Lymphoma 49, 615-619 (2008).
16. Li, J. et al. A chemical and phosphoproteomic characterization of dasatinib action in lung cancer. Nat. Chem. Biol. 6, 291-299 (2010).
17. Shi, H., Zhang, C.J., Chen, G.Y. & Yao, S.Q. Cell-based proteome profiling of potential dasatinib targets by use of affinity-based probes. J. Am. Chem. Soc. 134, 3001-3014 (2012).
18. Getlik, M. et al. Hybrid compound design to overcome the gatekeeper T338M mutation in cSrc. J. Med. Chem. 52, 3915-3926 (2009).
19. Best, M.D. Click chemistry and bioorthogonal reactions: unprecedented selectivity in the labeling of biological molecules. Biochemistry 48, 6571-6584 (2009).
20. Los, G.V. et al. HaloTag: a novel protein labeling technology for cell imaging and protein analysis. ACS Chem. Biol. 3, 373-382 (2008).
21. Jura, N. et al. Catalytic control in the EGF receptor and its connection to general kinase regulatory mechanisms. Mol. Cell 42, 9-22 (2011).
22. Engen, J.R. et al. Structure and dynamic regulation of Src-family kinases. Cell. Mol. Life Sci. 65, 3058-3073 (2008).
23. Briggs, S.D. & Smithgall, T.E. SH2-kinase linker mutations release Hck tyrosine kinase and transforming activities in Rat-2 fibroblasts. J. Biol. Chem. 274, 26579-26583 (1999).
24. Gonfloni, S., Frischknecht, F., Way, M. & Superti-Furga, G. Leucine 255 of Src couples intramolecular interactions to inhibition of catalysis. Nat. Struct. Biol. 6, 760-764 (1999).
25. Osusky, M., Taylor, S.J. & Shalloway, D. Autophosphorylation of purified c-Src at its primary negative regulation site. J. Biol. Chem. 270, 25729-25732 (1995).
26. Lerner, E.C. et al. Activation of the Src family kinase Hck without SH3-linker release. J. Biol. Chem. 280, 40832-40837 (2005).
27. Alvarado, J.J., Betts, L., Moroco, J.A., Smithgall, T.E. & Yeh, J.I. Crystal structure of the Src family kinase Hck SH3-SH2 linker regulatory region supports an SH3-dominant activation mechanism. J. Biol. Chem. 285, 35455-35461 (2010).
28. Ayrapetov, M.K. et al. Conformational basis for SH2-Tyr(P)527 binding in Src inactivation. J. Biol. Chem. 281, 23776-23784 (2006).
29. Lerner, E.C. & Smithgall, T.E. SH3-dependent stimulation of Src-family kinase autophosphorylation without tail release from the SH2 domain in vivo. Nat. Struct. Biol. 9, 365-369 (2002).
30. Moarefi, I. et al. Activation of the Src-family tyrosine kinase Hck by SH3 domain displacement. Nature 385, 650-653 (1997).
31. Wodicka, L.M. et al. Activation state-dependent binding of small molecule kinase inhibitors: structural insights from biochemistry. Chem. Biol. 17, 1241-1249 (2010).
32. Georghiou, G., Kleiner, R.E., Pulkoski-Gross, M., Liu, D.R. & Seeliger, M.A. Highly specific, bisubstrate-competitive Src inhibitors from DNA-templated macrocycles. Nat. Chem. Biol. 8, 366-374 (2012).
33. Sicheri, F., Moarefi, I. & Kuriyan, J. Crystal structure of the Src family tyrosine kinase Hck. Nature 385, 602-609 (1997).
34. Xu, W., Harrison, S.C. & Eck, M.J. Three-dimensional structure of the tyrosine kinase c-Src. Nature 385, 595-602 (1997).
35. Schindler, T. et al. Structural mechanism for STI-571 inhibition of abelson tyrosine kinase. Science 289, 1938-1942 (2000).
36. Seeliger, M.A. et al. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. Cancer Res. 69, 2384-2392 (2009).
37. Dar, A.C., Lopez, M.S. & Shokat, K.M. Small molecule recognition of c-Src via the Imatinib-binding conformation. Chem. Biol. 15, 1015-1022 (2008).
38. Simard, J.R. et al. A new screening assay for allosteric inhibitors of cSrc. Nat. Chem. Biol. 5, 394-396 (2009).
39. Wood, E.R. et al. A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res. 64, 6652-6659 (2004).
40. Marcotte, D.J. et al. Structures of human Bruton′s tyrosine kinase in active and inactive conformations suggest a mechanism of activation for TEC family kinases. Protein Sci. 19, 429-439 (2010).
41. Okuzumi, T. et al. Inhibitor hijacking of Akt activation. Nat. Chem. Biol. 5, 484-493 (2009).
42. Poulikakos, P.I., Zhang, C., Bollag, G., Shokat, K.M. & Rosen, N. RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF. Nature 464, 427-430 (2010).
43. Hatzivassiliou, G. et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth. Nature 464, 431-435 (2010).
44. Rauch, J., Volinsky, N., Romano, D. & Kolch, W. The secret life of kinases: functions beyond catalysis. Cell Commun. Signal. 9, 23 (2011).
45. Kaplan, K.B., Swedlow, J.R., Morgan, D.O. & Varmus, H.E. c-Src enhances the spreading of src-/- fibroblasts on fibronectin by a kinase-independent mechanism. Genes Dev. 9, 1505-1517 (1995).
46. García-Martínez, J.M. et al. A non-catalytic function of the Src family tyrosine kinases controls prolactin-induced Jak2 signaling. Cell. Signal. 22, 415-426 (2010).
47. Katsuta, H., Tsuji, S., Niho, Y., Kurosaki, T. & Kitamura, D. Lyn-mediated down-regulation of B cell antigen receptor signaling: inhibition of protein kinase C activation by Lyn in a kinase-independent fashion. J. Immunol. 160, 1547-1551 (1998).
48. Xu, H. & Littman, D.R. A kinase-independent function of Lck in potentiating antigen-specific T cell activation. Cell 74, 633-643 (1993).
49. Boudeau, J., Miranda-Saavedra, D., Barton, G.J. & Alessi, D.R. Emerging roles of pseudokinases. Trends Cell Biol. 16, 443-452 (2006).
50. Seeliger, M.A. et al. High yield bacterial expression of active c-Abl and c-Src tyrosine kinases. Protein Sci. 14, 3135-3139 (2005).